Glucoerysodine



Compound IDCDAMM00619
Common nameGlucoerysodine
IUPAC name2-[(2,12-dimethoxy-2,6,8,9-tetrahydro-1H-indolo[7a,1-a]isoquinolin-11-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
Molecular formulaC24H31NO8

Experimental data

Retention time0.42
Adduct[M+K]+
Actual mz500.168
Theoretical mz500.168
Error0.72
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.7307

Identifiers and class information

Inchi keyLDKVUIURMJHFPP-WDHHSZOHNA-N
SmilesOCC1OC(OC=2C=C3C(=CC2OC)C45C(C=CC(OC)C4)=CCN5CC3)C(O)C(O)C1O
SuperclassAlkaloids and derivatives
ClassErythrina alkaloids

Pharmacokinetic properties

Number of descriptor values(#stars)1
Number of non-conjugated amine groups (#amine)1
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)9
Number of reactive functional groups (#rtvFG)1
Predicted central nervous system activity (CNS)-1
Molecular weight (mol_MW)461.511
Computed dipole moment(dipole)4.162
Total solvent accessible surface area (SASA)677.672
Hydrophobic component of SASA (FOSA)415.217
Hydrophilic component of SASA (FISA)152.106
Pie component of the SASA (PISA)110.349
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1328.65
Number of hydrogen bond donors (donorHB)4
Number of hydrogen bond acceptors (accptHB)12.7
Free energy of solvation of dipole (dip^2/V)0.0130375
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0374812
Globularity descriptor (glob)0.862485
Predicted polarizability in cubic angstroms (QPpolrz)42.293
Predicted hexadecane/gas partition coefficient (QPlogPC16)13.276
Predicted octanol/gas partition coefficient (QPlogPoct)26.781
Predicted water/gas partition coefficient (QPlogPw)19.518
Predicted octanol/water partition coefficient (QPlogPo/w)0.791
Predicted aqueous solubility (QPlogS)-1.865
Conformation-independent predicted aqueous solubility (CIQPlogS)-3.127
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-5.01
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)89.203
Predicted brain/blood partition coefficient (QPlogBB)-0.944
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)40.153
Predicted skin permeability, log Kp (QPlogKp)-5.133
PM3 calculated ionization potential (IP(ev))8.536
PM3 calculated electron affinity (EA(eV))0.024
Number of likely metabolic reactions (#metab)9
Prediction of binding to human serum albumin (QPlogKhsa)-0.418
Predicted qualitative human oral absorption (HumanOralAbsorption)2
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)66.484
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)117.736
Number of nitrogen and oxygen atoms (#NandO)9
Number of violations of Lipinski’s rule of five (RuleOfFive)0
Number of violations of Jorgensen’s rule of three (RuleOfThree)1

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P43681CHRNA4Neuronal acetylcholine receptor; alpha4/beta2T70967SwissTargetPrediction
P36544CHRNA7Neuronal acetylcholine receptor protein alpha-7 subunitT34429SwissTargetPrediction
P29274ADORA2AAdenosine A2a receptorT77365SwissTargetPrediction
P12821ACEAngiotensin-converting enzymeT98311SwissTargetPrediction
P13866SLC5A1Sodium/glucose cotransporter 1T54771SwissTargetPrediction
P08473MMENeprilysinT05409SwissTargetPrediction
P35372OPRM1Mu opioid receptorT47768SwissTargetPrediction
P31639SLC5A2Sodium/glucose cotransporter 2T30085SwissTargetPrediction
P60568IL2Interleukin-2T61698SEA
P14679TYRTyrosinaseT97035SEA
Q9NZ08ERAP1Endoplasmic reticulum aminopeptidase 1T72849SEA
P16444DPEP1Renal dipeptidaseT41201SwissTargetPrediction

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T70967DI0029Aneurysm/dissection[ICD-11: BD50]P43681CHRNA4
T70967DI0191Hypertensive crisis[ICD-11: BA03]P43681CHRNA4
T70967DI0196Hypotension[ICD-11: BA20-BA21]P43681CHRNA4
T34429DI0101Corneal disease[ICD-11: 9A76-9A78]P36544CHRNA7
T34429DI0370Schizophrenia[ICD-11: 6A20]P36544CHRNA7
T77365DI0319Orthostatic hypotension[ICD-11: BA21]P29274ADORA2A
T77365DI0331Parkinsonism[ICD-11: 8A00]P29274ADORA2A
T77365DI0359Radionuclide imaging[ICD-11: N.A.]P29274ADORA2A
T98311DI0175Heart failure[ICD-11: BD10-BD1Z]P12821ACE
T98311DI0190Hypertension[ICD-11: BA00-BA04]P12821ACE
T54771DI0120Diabetes mellitus[ICD-11: 5A10]P13866SLC5A1
T54771DI0175Heart failure[ICD-11: BD10-BD1Z]P13866SLC5A1
T54771DI0417Type 2 diabetes mellitus[ICD-11: 5A11]P13866SLC5A1
T05409DI0175Heart failure[ICD-11: BD10-BD1Z]P08473MME
T47768DI0013Acute pain[ICD-11: MG31]P35372OPRM1
T47768DI0059Bowel habit change[ICD-11: ME05]P35372OPRM1
T47768DI0087Chronic pain[ICD-11: MG30]P35372OPRM1
T47768DI0101Corneal disease[ICD-11: 9A76-9A78]P35372OPRM1
T47768DI0105Cough[ICD-11: MD12]P35372OPRM1
T47768DI0117Depression[ICD-11: 6A70-6A7Z]P35372OPRM1
T47768DI0124Digestive system disease[ICD-11: DE2Z]P35372OPRM1
T47768DI0218Irritable bowel syndrome[ICD-11: DD91]P35372OPRM1
T47768DI0228Large intestine motility disorder[ICD-11: DB32]P35372OPRM1
T47768DI0317Opioid use disorder[ICD-11: 6C43]P35372OPRM1
T47768DI0324Pain[ICD-11: MG30-MG3Z]P35372OPRM1
T47768DI0349Pruritus[ICD-11: EC90]P35372OPRM1
T47768DI0374Sensation disturbance[ICD-11: MB40]P35372OPRM1
T30085DI0120Diabetes mellitus[ICD-11: 5A10]P31639SLC5A2
T30085DI0175Heart failure[ICD-11: BD10-BD1Z]P31639SLC5A2
T30085DI0417Type 2 diabetes mellitus[ICD-11: 5A11]P31639SLC5A2
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR
T41201DI0046Bacterial infection[ICD-11: 1A00-1C4Z]P16444DPEP1

Copyright © 2025